Achieve high success rates
Achieve double-digit success rates (>10%) for antibodies and extremely high success rates (>50%) for miniproteins to bypass screening.
Achieve double-digit success rates (>10%) for antibodies and extremely high success rates (>50%) for miniproteins to bypass screening.
Faster experimentation cycles
Avoid high-throughput screening and go straight to characterization in <2 weeks.
Avoid high-throughput screening and go straight to characterization in <2 weeks.
Target specific antigen confirmations
Design explicitly for agonism or antagonism by targeting a specific antigen state, which can be difficult to isolate for traditional methods.
Design explicitly for agonism or antagonism by targeting a specific antigen state, which can be difficult to isolate for traditional methods.
Address challenging targets
Target membrane proteins without the need for lab-based workarounds such as like antigen mimetics.
Target membrane proteins without the need for lab-based workarounds such as like antigen mimetics.
Design for epitope specificity
Choose an epitope on the target structure, or let the model choose for you. Target small, buried, or non-immunogenic epitopes.
Choose an epitope on the target structure, or let the model choose for you. Target small, buried, or non-immunogenic epitopes.
Handle chemical modifications
Target epitopes with bound ligands or post-translational modifications (PTMs) such as glycans.
Target epitopes with bound ligands or post-translational modifications (PTMs) such as glycans.